Mechanistic basis of adverse drug reactions: The perils of inappropriate dose schedules

Expert Opinion on Drug Safety

Volumn 4, Issue 1, 2005, Pages 103-128

  Shah, Rashmi R ^a  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

Author keywords

Adverse drug reactions (ADRs); Cisapride; Co morbidity; Cytochrome P450 (CYP); Dose schedules; Drug interactions; Efflux pumps; Glucuronidation; Impaired clearance; P glycoprotein; Polymorphic pharmacology; Stereoselective pharmacology; Transporters

Indexed keywords

6 METHYLTHIOINOSINE; ANTIARRHYTHMIC AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ASTEMIZOLE; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CERIVASTATIN; CISAPRIDE; CODEINE; CYCLOOXYGENASE 2 INHIBITOR; FLOSEQUINAN; FLUOXETINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISONIAZID; NORASTEMIZOLE; ORAL ANTIDIABETIC AGENT; PHENYTOIN; PIMOZIDE; PROCAINAMIDE; PSYCHOTROPIC AGENT; RIFAMPICIN; ROSUVASTATIN; SIMVASTATIN; TERODILINE; UNINDEXED DRUG; WARFARIN;

ANTIARRHYTHMIC ACTIVITY; APLASTIC ANEMIA; BLEEDING; BLOOD BRAIN BARRIER; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRONCHOSPASM; CARDIOTOXICITY; CLINICAL TRIAL; COLLAPSE; CONCENTRATION RESPONSE; CONFUSION; CONGESTIVE HEART FAILURE; CONSULTATION; CONVULSION; DIET; DISEASE SEVERITY; DRUG ACETYLATION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MARKETING; DRUG METABOLISM; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG SURVEILLANCE PROGRAM; DRUG TRANSPORT; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; EOSINOPHILIA MYALGIA SYNDROME; EXTRAPYRAMIDAL SYMPTOM; FOOD DRUG INTERACTION; GASTROINTESTINAL TRACT; GENE MUTATION; GENETIC POLYMORPHISM; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HEART PROARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HEMATOLOGIC DISEASE; HEMOLYTIC ANEMIA; HEPATITIS; HEPATOBILIARY SYSTEM; HEREDITY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPERBILIRUBINEMIA; HYPERLIPIDEMIA; HYPOGLYCEMIA; HYPOTENSION; ISCHEMIC COLITIS; KIDNEY FAILURE; KIDNEY TUBULE; LACTIC ACIDOSIS; LIVER TOXICITY; MENTAL DISEASE; MORBIDITY; MORTALITY; MYOPATHY; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; ORTHOSTATIC HYPOTENSION; PHARMACODYNAMICS; PHYTOCHEMISTRY; PROTEIN EXPRESSION; PROTEIN INTERACTION; PULMONARY HYPERTENSION; QT PROLONGATION; REVIEW; RHABDOMYOLYSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SKIN MANIFESTATION; TORSADE DES POINTES; TUBERCULOSIS; VALVULAR HEART DISEASE; VOMITING; WEIGHT REDUCTION;

CISAPRIDE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY; GASTROINTESTINAL AGENTS; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; POLYMORPHISM, GENETIC;

EID: 12544251868     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.4.1.103     Document Type: Review

References (202)

1. MULROY R. Iatrogenic disease in general practice. Its incidence and effects. Br. Med. J. (1973) 2:407-410.
2. HARAMBURU F, POUYANNE P, IMBS JL, BLAYAC JP, BEGAUD B: [Incidence and prevalence of adverese drug reactions]. Presse Med. (2000) 29:111-114. French.
3. RASCHETTI R, MORGUTTI M, MENNITI-IPPOLITO F et al.: Suspected adverse drug events requiring emergency department visits or hospital admissions. Eur. J. Clin. Pharmacol. (1999) 54 959-963.
4. HALLAS J, GRAM LF, GRODUM E et al.: Drug related admissions to medical wards: a population based survey. Br. J. Clin. Pharmacol. (1992) 33:61-68.
5. MJÖRNDAL T, DANELL BOMAN M, HÄGG S et al.: Adverse drug reactions as a cause for admissions to a department of internal medicine. Pharmacoepidemiol. Drug Saf. (2002) 11 65-72.
6. DARTNELL JG, ANDERSON RP, CHOHAN V et al.: Hospitalisation for adverse events related to drug therapy: incidence, avoidability and costs. Med. J. Aust. (1996) 164:659-662.
7. NELSON KM, TALBERT RL: Drug-related hospital admissions. Pharmacotherapy (1996) 16:701-707.
8. GREEN CF, MOTTRAM DR, ROWE PH, PIRMOHAMED M: Adverse drug reactions as a cause of admission to an acute medical assessment unit a pilot study. J. Clin. Pharm. Ther. (2000) 25:355-361.
9. BEIJER HJ, DE BLAEY CJ: Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm. World Sci. (2002) 24:46-54.
10. FATTINGER K, ROOS M, VERGERES P et al.: Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br. J. Clin. Pharmacol. (2000) 49:158-167.
11. WASSERFALLEN J, LIVIO F, BUCLIN T, TILLET L, YERSIN B, BIOLLAZ J: Rate, type and cost of adverse drug reactions in emergency department admissions. Eur. J. Intern. Med. (2001) 12 442-447.
12. POUYANNE P, HARAMBURU F, IMBS JL, BEGAUD B: Admissions to hospital caused by adverse drug reactions: cross sectional incidence study, French Pharmacovigilance Centres. Br. Med. J. (2000) 320 1036.
13. LAGNAOUI R, MOORE N, FACH J, LONGY-BOURSIER M, BEGAUD B: Adverse drug reactions in a department of systemic diseases orientated internal medicine: prevalence, incidence, direct costs and avoidability. Eur. J. Clin. Pharmacol. (2000) 56:181-186.
14. SCHNEEWEISS S, HASFORD J, GOTTLER M, HOFFMANN A, RIETHLING AK, AVORN J: Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur. J. Clin. Pharmacol. (2002) 58 285-291.
15. MOORE N, LECOINTRE D, NOBLET C, MABILLE M: Frequency and cost of serious adverse drug reactions in a department of general medicine. Br. J. Clin. Pharmacol. (1998) 45:301-308.
16. SUH DC, WOODALL BS, SHIN SK, HERMES-DE-SANTIS ER: Clinical and economic impact of adverse drug reactions in hospitalised patients. Ann. Pharmacother. (2000) 34:1373-1379.
17. PIRMOHAMED M, JAMES S. MEAKIN S et al.: Adverse drug reactions as cause of admissions to hospitals: prospective analysis of 18 820 patients. Br. Med. J. (2004) 329:15-19.
18. SHAPIRO S, SLONE D, LEWIS GP, JICK H: Fatal drug reactions among medical inpatients. JAMA (1971) 216:467-472.
19. LAZAROU J, POMERANZ BH, COREY PN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA (1998) 279:1200-1205.
20. VARGAS E, NAVARRO MI, LAREDO L, GARCIA-ARENILLAS M, GARCIA-MATEOS M, MORENO A: Effect of drug interactions on the development of adverse drug reactions. Clin. Drug Invest. (1997) 13 282-298.
21. KONTORINIS N, AGARWAL K, GONDOLESI G, FIEL MI, O'ROURKE M, SCHIANO TD: Diagnosis of 6 mercaptopurine hepatotoxicity post liver transplantation utilizing metabolite assays. Am. J. Transplant. (2004) 4:1539-1542.
22. OHNO M, YAMAGUCHI I, YAMAMOTO I et al.: Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int. J. Tuberc. Lung Dis. (2000) 4:256-261.
23. HUANG YS, CHERN HD, SU WJ et al.: Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology (2003) 37:924-930.
24. YUE J, PENG RX, YANG J, KONG R, LIU J: CYP2E1 mediated isoniazid-induced hepatotoxicity in rats. Acta. Pharmacol. Sin. (2004) 25:699-704.
25. SHAH RR: Improving clinical risk/benefit through stereochemistry In: Handbook of Experimental Pharmacology (Volume 153). Stereochemical Aspects of Drug Action and Disposition. Eichelbaum M, Testa B, Somogyi A (Eds), Springer-Verlag, Berlin (2003):401-432.
26. GIBALDI M: Stereoselective and isozyme-selective drug interactions. Chirality (1993) 5:407-413.
27. KAMINSKY LS, ZHANG ZY: Human P450 metabolism of warfarin. Pharmacol. Ther. (1997) 73:67-74.
28. BRECKENRIDGE A, ORME M, WESSLING H, LEWIS RJ, GIBBONS R: Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin. Pharmacol. Ther. (1974) 15:424-430.
29. O'REILLY RA, GOULART DA, KUNZE KL et al.: Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin. Pharmacol. Ther. (1992) 51:656-667.
30. BLACK DJ, KUNZE KL, WIENKERS LC et al.: Warfarin-Fluconazole II: a metabolically based drug interaction: in vivo studies. Drug Metab. Dispos. (1996) 24:422-428.
31. WIENKERS LC, WURDEN CJ, STORCH E, KUNZE KL, RETTIE AE, TRACER WF: Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metab. Dispos. (1996) 24:610-614.
32. LU P, SCHRAG ML, SLAUGHTER DE, RAAB CE, SHOU M, RODRIGUES AD: Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab. Dispos. (2003) 31:1352-1360.
33. ANDERSSON T, HASSAN-ALIN M, HASSELGREN C, ROHSS K: Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin. Pharmacokinet. (2001) 40:523-537.
34. MEADOWROFT AM, WILLIAMSON KM, PATTERSON JH, PIEPER JA: Pharmacogenetics and heart failure: a convergence with carvedilol. Pharmacotherapy (1997) 17:637-639.
35. FULOP C, PHILLIPS RA, SHAPIRO AK, COMES JA, SHAPIRO E, NORDLIE JW: ECG changes during haloperidol and pimozide treatment of Tourette's disorder. Am. J. Psychiatry (1987) 144:673-675.
36. VOLPERIAN VR, ZHOU Z, MOHAMMAD S, HOON TJ, STUDENIK C, JANUARY CT: Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole. J. Am. Coll. Cardiol. (1996) 28:1556-1561.
37. ZHOU Z, VOLPERIAN VR, GONG Q, ZHANG S, JANUARY CT: Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J. Cardiovasc. Electrophysiol. (1999) 10:836-843.
38. ANON: Cardiotoxicity of astemizole in overdose - dosing is critical. Committee on Safety of Medicines, London. Current Problems (1987) 19:1-2.
39. CRAFT TM: Torsade de pointes after astemizole overdose. Br. Med. J. (1986) 292:660.
40. ANON: Toxicity problems with high-dose Zocor. Scrip (1997) 2235:21.
41. BANNWARTH B: Drug-induced myopathies. Expert Opin. Drug Saf. (2002) 1:65-70.
42. CROSS J, LEE H, WESTELINCK A, NELSON J, GRUDZINSKAS C, PECK C: Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999. Pharmacoepidemiol. Drug Saf. (2002) 11 439-446.
43. COHEN JS: Dose discrepancies between the Physicians' Desk Reference and the medical literature, and their possible role in the high incidence of dose-related adverse drug events. Arch. Intern. Med. (2001) 161:957-964.
44. BARRON HV, VISKIN S, LUNDSTROM RJ et al.: Beta-blocker dosages and mortality after myocardial infarction: data from a large health maintenance organization. Arch. Intern. Med. (1998) 158 449-453.
45. PACKERM, ROULEAU J, SWEDBERG K et al.: Effect of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE study. Circulation (1993) 88(Suppl. 1):301.
46. EVANS DA, MANLEY KA, MCKUSICK VA: Genetic control of isoniazid metabolism in man. Br. Med. J. (1960) 2:485-491.
47. PRICE-EVANS DA, MAHGOUB A, SLOAN TP, IDLE JR, SMITH RL: A family and population study of the genetic polymorphism of debrisoquine oxidation in a British white population. J. Med. Genet. (1980) 17:102-105.
48. ZANGER UM, RAIMUNDO S, EICHELBAUM M: Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn. Schmiedebergs Arch. Pharmacol. (2004) 369:23-37.
49. SHAH RR, OATES NS, IDLE JR, SMITH RL, LOCKHART JD: Impaired oxidation of debrisoquine in patients with perhexiline-neuropathy. Br. Med. J. (1982) 284:295-299.
50. MORGAN MY, RESHEF R, SHAH RR, OATES NS, SMITH RL, SHERLOCK S: Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut (1984) 25:1057-1064.
51. SALLUSTIO BC, WESTLEY IS, MORRIS RG: Pharmacokinetics of the antianginal agent perhexiline relationship between metabolic ratio and steady-state dose. Br. J. Clin. Pharmacol. (2002) 54:107-114.
52. MEYER UA: Pharmacogenetics and adverse drug reactions. Lancet (2000) 356:1667-1671.
53. KIRCHHEINER J, BRØSEN K, DAHL ML et al.: CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta. Psychiatr. Scand. (2001) 104:173-192.
54. HIGASHI MK, VEENASTRA DL, KONDO LM et al.: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA (2002) 287:1690-1698.
55. VAN DER WEIDE J, STEIJNS LS, VAN WEELDEN MJ, DE HAAN K: The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics (2001) 11:287-291.
56. TAKAHASHI H, ECHIZEN H: Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmacogenomics J. (2003) 3:202-214.
57. KAMALI F, KHAN TI, KING BP et al.: Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin. Pharmacol. Ther. (2004) 75:204-212.
58. VERSTUYFT C, ROBERT A, MORIN S et al.: Genetic and environmental risk factors for oral anticoagulant overdose. Eur. J. Clin. Pharmacol. (2003) 58:739-745.
59. PEYVANDI F, SPREAFICO M, SIBONI SM, MOIA M, MANNUCCI PM: CYP2C9 genotype and dose requirements during induction phase of oral anticoagulant therapy. Clin. Pharmacol. Ther. (2004) 75 198-203.
60. LOEBSTEIN R, YONATH H, PELEG D et al.: Interindividual variability in sensitivity to warfarin - nature or nurture? Clin. Pharmacol. Ther. (2001) 70:159-164.
61. MALHI H, ATAC B, DALY AK, GUPTA S: Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication. Postgrad. Med. J. (2004) 80:107-109.
62. LENNARD L, VAN LOON JA, LILLEYMAN JS, WEINSHILBOUM RM: Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin. Pharmacol. Ther. (1987) 41:18-25.
63. SCHAEFFELER E, FISCHER C, BROCKMEIER D et al.: Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics (2004) 14:407-417.
64. DAI D, ZELDIN DC, BLAISDELL JA et al.: Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics (2001) 11:597-607.
65. YASAR U, LUNDGREN S, ELIASSON E et al.: Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem. Biophys. Res. Commun. (2002) 299:25-28.
66. PHILLIPS KA, VEENSTRA DL, OREN E, LEE JK, SADEE W: Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA (2001) 286:2270-2279.
67. GUILLEMETTE C: Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J. (2003) 3:136-158.
68. BURCHELL B: Genetic variation of human UDP-glucuronosyltransferase: implications in disease and drug glucuronidation. Am. J. Pharmacogenomics (2003) 3:37-52.
69. INNOCENTI F, UNDEVIA SD, IYER L et al.: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. (2004) 22 1382-1388.
70. IYER L, DAS S, JANISCH L et al.: UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. (2002) 2:43-47.
71. INNOCENTI F, STADLER WM, IYER L, RAMIREZ J, VOKES EE, RATAIN MJ: Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. Clin. Cancer Res. (2000) 6:3400-3405.
72. RAMIREZ J, IYER L, JOURNAULT K et al.: In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes. Pharm. Res. (2002) 19 588-594.
73. ANON: FDA notifications. Reyataz is approved for HIV treatment. Aids Alert (2003) 18:119-120.
74. SHAW P: Pharmacogenetic applications in clinical development. International Clinical Trials Symposium. Sydney; 21-23 October 2002
75. DANOFF TM, CAMPBELL DA, MCCARTHY LC et al.: A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinaemia. Pharmacogenomics J. (2004) 4:49-53.
76. EHOLIÉ SP, LACOMBE K, SERFATY L, WENDUM D, GIRARD P-M: Acute hepatic cytolysis in an HIV-infected patient taking atazanavir. AIDS (2004) 18:1610-1611.
77. HOFFMEYER S, BURK O, VON RICHTER O et al.: Functional polymorphisms of the human multidrug-resistance gene multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA (2000) 97 3473-3478.
78. KIM RB, LEAKE BF, CHOO EF et al.: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. (2001) 70:189-199.
79. EICHELBAUM M, FROMM MF, SCHWAB M: Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther. Drug Monit. (2004) 26 180-185.
80. SAKAEDA T, NAKAMURA T, OKUMURA K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics (2003) 4:397-410.
81. PARKER RB, YATES CR, SOBERMAN JE, LAIZURE SC: Effects of grapefruit juice on intestinal P-glycoprotein: evaluation using digoxin in humans. Pharmacotherapy (2003) 23:979-987.
82. MILNE RW, LARSEN LA, JORGENSEN EL, BASTLUND J, STRETCH CR, EVANS AM: Hepatic disposition of fexofenadine: influence of the transport inhibitors erythromycin and dibromosulphothalein. Pharm. Res. (2000) 17:1511-1515.
83. ZHANG L, DRESSER MJ, GRAY AT, YOST SC, TERASHITA S, GIACOMINI KM: Cloning and functional expression of a human liver organic cation transporter. Mol. Pharmacol. (1997) 51:913-921.
84. TIRONA RG, LAEKE BF, MERINO G, KIM RB: Polymorphisms in OATP-C: Identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J. Biol. Chess. (2001) 276:35669-35675.
85. MURATA M, TAMAI I, SAI Y et al.: Hepatobiliary transport kinetics of HSR-903, a new quinolone antibacterial agent. Drug Metab. Dispos. (1998) 26:1113-1119.
86. FOUASSIER L, KINNMAN N, LEFEVRE C et al.: Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan. J. Hepatol. (2002) 37:184-191.
87. NOZAWA T, NAKAJIMA M, TAMAI I et al.: Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J. Pharmacol. Exp. Ther. (2002) 302 804-813.
88. MURPHY GM Jr, KREMER C, RODRIGUES HE, SCHATZBERG AF: Pharmacogenetics of antidepressant medication intolerance. Am. J. Psychiatry (2003) 160:1830-1835.
89. KAISER R, SEZER O, PAPIES A et al.: Patient-tailored antiemetic treatment with 5-hydroxytryptamine Type 3 receptor antagonists according to cytochrome P450 2D6 genotypcs. J. Clin. Oncol. (2002) 20:2805-2811.
90. TREMBLAY PB, KAISER R, SEZER O et al.: Variations in the 5-hydroxytryptamine Type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J. Clin. Oncol. (2003) 21:2147-2155.
91. LIGGETT SB, WAGONER LE, CRAFT LL et al.: The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J. Clin. Invest. (1998) 102 1534-1539.
92. WAGONER LE, CRAFT LL, ZENGEL P et al.: Polymorphisms of the beta1-adrenergic receptor predict exercise capacity in heart failure. Am. Heart J. (2002) 144:840-846.
93. BORJESSON M, MAGNUSSON Y, HJALMARSON A, ANDERSSON B: A novel polymorphism in the gene coding for the beta1-adrenergic receptor associated with survival in patients with heart failure. Eur. Heart J. (2000) 21:1853-1858.
94. KAYE DM, SMIRK B, WILLIAMS C, JENNINGS C, ESLER M, HOLST D: Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics (2003) 13:379-382.
95. SHAH RR: The significance of QT interval in drug development. Br. J. Clin. Pharmacol. (2002) 54:188-202.
96. ANON: Prenylamine withdrawn in UK. Scrip (1988) 1300 26.
97. SPLAWSKI I, SHEN J, TIMOTHY KW et al.: Spectrum of mutations in long QT syndrome genes KVLQT1, HERG, SCN5A, KCNE1 and KCNE2. Circulation (2000) 102:1178-1185.
98. WANG Q, CURRAN ME, SPLAWSKI I et al.: Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat. Genet. (1996) 12:17-23.
99. VINCENT GM, TIMOTHY KW, LEPPERT M, KEATING M: The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. N. Engl. J. Med. (1992) 327:846-852.
100. SAARINEN K, SWAN H, KAINULAINEN K, TOIVONEN L, VIITASALO M, KONTULA K: Molecular genetics of the long QT syndrome: two novel mutations of the KVLQT1 gene and phenotypic expression of the mutant gene in a large kindred. Hum. Mutat. (1998) 11:158-165.
101. PRIORI SC, NAPOLITANO C, SCHWARTZ PJ: Low penetrance in the long-QT syndrome clinical impact. Circulation (1999) 99 529-533.
102. SHAH RR: Pharmacogenetic aspects of drug-Induced torsade de pointes: potential tool for improving clinical drug development and prescribing. Drug Saf. (2004) 27:145-172.
103. WYSOWSKI DK, CORKEN A, GALLO-TORRES H, TALARICO L, RODRIGUEZ EM: Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am. J. Gastroenterol. (2001) 96:1698-1703.
104. YANG P, KANKI H, DROLET B et al.: Alleic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation (2002) 105:1943-1948.
105. PAULUSSEN AD, GILISSEN RA, ARMSTRONG M et al.: Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J. Mol. Med. (2004) 82:182-188.
106. CHASMAN DI, POSADA D, SUBRAHMANYAN L, COOK NR, STANTON VP, RIDKER PM: Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA (2004) 291:2821-2827.
107. JANKEL CA, SPEEDIE SM: Detecting drug interactions: a review of the literature. DICP. Ann. Pharmacother. (1990) 24 982-989.
108. DALLENBACH MF, DESMEULES J, BOVIER P, DAYER P: Drug interaction detection using Epocrates in a walk-in clinic. Clin. Pharmacol. Ther. (2003) 73:P11(Abstract PI-39).
109. MCDONNELL PJ, JACOBS MR: Hospital admissions resulting from preventable adverse drug reactions. Ann. Pharmacother. (2002) 36 1331-1336.
110. DOUCET J, CHASSAGNE P, TRIVALLE C et al.: Drug-drug interactions related to hospital admissions in older adults: a prospective study of 1000 patients. J. Am. Geriatr. Soc. (1996) 44:944-948.
111. CURTIS LH, OSTBYE T, SENDERSKY V et al.: Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am. J. Med. (2003) 114:135-141.
112. DRUID H, HOLMGREN P, CARLSSON B, AHLNER J: Cytochrome P450 2D6 (CYP2D6) genotyping on postmortem blood as a supplementary tool for interpretation of forensic toxicological results. Forensic Sci. Int. (1999) 99:25-34.
113. DILGER K, GREINER B, FROMM MF, HOFMANN U, KROEMER HK, EICHELBAUM M: Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. Pharmacogenetics (1999) 9:551-559.
114. CARACO Y, SHELLER J, WOOD AJ: Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. J. Pharmacol. Exp. Ther. (1999) 290:413-422.
115. MORIKE KE, RODEN DM: Quinidine-enhanced beta-blockade during treatment with propafenone in extensive metabolizer human subjects. Clin. Pharmacol. Ther. (1994) 55:28-34.
116. TURGEON J, FISET C, GIGUERE R et al.: Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. J. Pharmacol. Exp. Ther. (1991) 259:789-798.
117. TURGEON J, PAVLOU HN, WONG W, FUNCK-BRENTANO C, RODEN DM: Genetically determined steady-state interaction between encainide and quinidine in patients with arrhythmias. J. Pharmacol. Exp. Ther. (1990) 255:642-649.
118. HAMELIN BA, BOUAYAD A, METHOT J et al.: Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin. Pharmacol. Ther. (2000) 67:466-477.
119. BROSEN K, HANSEN JG, NIELSEN KK, SINDRUP SH, GRAM LF: Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur. J. Clin. Pharmacol. (1993) 44:349-355.
120. RETTIE AE, RETTENMEIER AW, HOWALD WN, BAILLIE TA: Cytochrome P450-catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid. Science (1987) 235:890-893.
121. OTTON SV, WU D, JOFFE RT, CHEUNG SW, SELLERS EM: Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin. Pharmacol. Ther. (1993) 53:401-409.
122. AMCHIN J, ERESHEFSKY L, ZARYCRANSKI W, TAYLOR K, ALBANO D, KLOCKOWSKI PM: Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe. J. Clin. Pharmacol. (2001) 41 443-451.
123. HEMERYCK A, BELPAIRE FM: Selective serotonin reuptake inhibitors and cytochrome P450 mediated drug-drug interactions: an update. Curr. Drug Metab. (2002) 3:13-37.
124. MULLINS ME, HOROWITZ BZ, LINDEN DH, SMITH GW, NORTON RL, STUMP J: Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers. JAMA (1998) 280 157-158.
125. OKUDA H, NISHIYAMA T, OGURA K et al.: Lethal drug interactions of sorivudine, anew antiviral drug, with oral 5-fluorouracil prodrugs. Drug Metab. Dispos. (1997) 25:270-273.
126. KANAMITSU SI, ITO K, OKUDA H et al.: Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-bromovinyl)uracil. Drug Metab. Dispos. (2000) 28 467-474.
127. MARROUM PJ, UPPOOR RS, PARMELEE T et al.: In vivo drug-drug interaction studies - a survey of all new molecular entities approved from 1987 to 1997. Clin. Pharmacol. Ther. (2000) 68 280-285.
128. KIRCHNER GI, MEIER-WIEDENBACH I, MANNS MP: Clinical pharmacokinetics of everolimus. Clin. Pharmacokinet. (2004) 43 83-95.
129. KIMURA Y, AOKI J, KOHNO M, OOKA H, TSURUO T, NAKANISHI O: P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel. Cancer Chemother. Pharmacol. (2002) 49 322-328.
130. KEMPER EM, VAN ZANDBERGEN AE, CLEYPOOL C et al.: Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein. Clin. Cancer Res. (2003) 9:2849-2855.
131. ABEL S, NICHOLS DJ, BREARLEY CJ, EVE MD: Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide. Br. J. Clin. Pharmacol. (2000) 49:64-71.
132. BANFIELD C, GUPTA S, MARINO M, LIM J, AFFRIME M: Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin. Pharmacokinet. (2002) 41:311-318.
133. HAMMAN MA, BRUCE MA, HAEHNER-DANIELS BD, HALL SD: The effect of rifampin administration on the disposition of fexofenadine. Clin. Pharmacol. Ther. (2001) 69:114-121.
134. SCHNECK DW, BIRMINGHAM BK, ZALIKOWSKI JA et al.: The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin. Pharmacol. Ther. (2004) 75:455-463.
135. BACKMAN JT, KYRKLUND C, NEUVONEN M, NEUVONEN PJ: Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin. Pharmacol. Ther. (2002) 72:685-691.
136. WANG JS, NEUVONEN M, WEN X, BACKMAN JT, NEUVONEN PJ: Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab. Dispos. (2002) 30:1352-1356.
137. SHITARA Y, HIRANO M, SATO H, SUGIYAMA Y: Gemfibrozil and its glucuronide inhibit the OATP2 (OATP1B1: SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin - analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther. (2004) Epub ahead of print.
138. TREIBER A, SCHNEITER R, DELAHAYE S, CLOZEL M: Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat. J. Pharmacol. Exp. Ther. (2004) 308 1121-1129.
139. SCHWAB M, EICHELBAUM M, FROMM MF: Genetic polymorphisms of the human MDR1 drug transporter. Ann. Rev. Pharmacol. Toxicol. (2003) 43:285-307.
140. MARZOLINI C, PAUSE, BUCLIN T, KIM RB: Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. (2004) 75:13-33.
141. CHANDRA P, BROUWER KL: The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm. Res. (2004) 21:719-735.
142. ELSINGA PH, HENDRIKSE NH, BART J, VAALBURG W, VAN WAARDE A: PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Curr. Pharm. Des. (2004) 10:1493-1503.
143. MARZOLINI C, TIRONA RG, KIM RB: Pharmacogenomics of the OATP and OAT families. Pharmacogenomics (2004) 5:273-282.
144. ERALY SA, BUSH KT, SAMPOGNA RV, BHATNAGAR V, NIGAM SK: The molecular pharmacology of organic anion transporters: from DNA to FDA? Mol. Pharmacol. (2004) 65:479-487.
145. KUNTA JR, SINKO PJ: Intestinal drug transporters: in vivo function and clinical importance. Curr. Drug. Metab. (2004) 5 109-124.
146. YOU C: The role of organic ion transporters in drug disposition: an update. Curr. Drug. Metab. (2004) 5:55-62.
147. LEE W, KIM RB: Transporters and renal drug elimination. Ann. Rev. Pharmacol. Toxicol. (2004) 44:137-166.
148. LIN JH, YAMAZAKI M: Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin. Pharmacokinet. (2003) 42:59-98.
149. IEIRI I, TAKANE H, OTSUBA K: The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin. Pharmacokinet. (2004) 43:553-576.
150. DE LANGE EC, DANHOF M: Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin. Pharmacokinet. (2002) 41 691-703.
151. FROMM MF: Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol. Sci. (2004) 25:423-429.
152. ROE CM, ODELL KW, HENDERSON RR: Concomitant use of antipsychotics and drugs that may prolong the QT interval. J. Clin. Psychopharmacol. (2003) 23:197-200.
153. KIIVET RA, LLERENA A, DAHL ML et al.: Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden. Br. J. Clin. Pharmacol. (1995) 40:467-476.
154. PROCYSHYN EM, KENNEDY NB, TSE G, THOMPSON B: Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can. J. Psychiatry (2001) 46 334-339.
155. CENTORRINO F, GOREN JL, HENNEN J, SALVATORE P, KELLEHER JP, BALDESSARINI RJ: Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am. J. Psychiatry (2004) 161:700-706.
156. TANAKA E: Clinical importance of non-genetic and genetic cytochrome P450 function tests in liver disease. J. Clin. Pharm. Ther. (1998) 23:161-170.
157. YANG LQ, LI SJ, CAO YF et al.: Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases. World J. Gastroenterol. (2003) 9 359-363.
158. ADEDOYIN A, ARNS PA, RICHARDS WO, WILKINSON GR, BRANCH RA: Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochrome P450 2C19 and 2D6. Clin. Pharmacol. Ther. (1998) 64:8-17.
159. OKERHOLM RA, WEINER DL, HOOK RH et al.: Bioavailabiity of terfenadine in man. Biopharm. Drug Dispos. (1981) 2 185-190.
160. GOLDBERG MJ, RING B, DESANTE K et al.: Effect of dirithromycin on human CYP3A in vitro and on pharmacokinetics and pharmacodynamics of terfenadine in vivo. J. Clin. Pharmacol. (1996) 36:1154-1160.
161. KAMISAKO T, ADACHI Y, NAKAGAWA H, YAMAMOTO T: Torsades de pointes associated with terfenadine in a case of liver cirrhosis and hepatocellular carcinoma. Intern. Med. (1995) 34:92-95.
162. WOOSLEY RL: Cardiac actions of antihistamines. Ann. Rev. Pharmacol. Toxicol. (1996) 36:233-252.
163. LANTHIER PL, RESHEF R, SHAH RR, OATES NS, SMITH RL, MORGAN MY: Oxidation phenotyping in alcoholics with liver disease of varying severity. Alcohol Clin. Exp. Res. (1984) 8:435-441.
164. ROWE JW, ANDRES R, TOBIN JD: Age-adjusted standards for creatinine clearance. Ann. Intern. Med. (1976) 84:567-569.
165. DREISBACH AW, LERTORA JJ: The effect of chronic renal failure on hepatic drug metabolism and drug disposition. Semin. Dial. (2003) 16:45-50.
166. CUEVIN C, MICHAUD J, NAUD J, LEBLOND FA, PICHETTE V: Down-regulation of hepatic cytochrome P450 in chronic renal failure role of uremic mediators. Br. J. Pharmacol. (2002) 137:1039-1046.
167. PICHETTE V, LEBLOND FA: Drug metabolism in chronic renal failure. Curr. Drug Metab. (2003) 4:91-103.
168. KIM YG, SHIN JG, SHIN SG et al.: Decreased acetylation of isoniazid in chronic renal failure. Clin. Pharmacol. Ther. (1993) 54:612-620.
169. DOWLING TC, BRIGLIA AE, FINK JC et al.: Characterization of hepatic cytochrome P4503A activity in patients with end-stage renal disease. Clin. Pharmacol. Ther. (2003) 73 427-434.
170. ROSTAMI-HODJEGAN A, KROEMER HK, TUCKER GT: In-vivo indices of enzyme activity: the effect of renal impairment on the assessment of CYP2D6 activity. Pharmacogenetics (1999) 9:277-286.
171. DREISBACH AW, JAPA S, GEBREKAL AB et al.: Cytochrome P4502C9 activity in end-stage renal disease. Clin. Pharmacol. Ther. (2003) 73:475-477.
172. SHAH RR: Drug development and use in the elderly: Search for the right dose and dosing regimen. Br. J. Clin. Pharmacol. (2004) 58:452-469.
173. TURNHEIM K: Drug therapy in the elderly. Exp. Gerontol. (2004) 39:1731-1738.
174. HAMMERLEIN A, DERENDORF H, LOWENTHAL DT: Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications. Clin. Pharmacokinet. (1998) 35:49-64.
175. VUYK J: Pharmacodynamics in the elderly. Best Pract. Res. Clin. Anaesthesiol. (2003) 17:207-218.
176. NÄBAUER M, KÄÄB S: Potassium channel down-regulation in heart failure. Cardiovasc. Res. (1998) 37:324-334.
177. PRIORI SC: Exploring the hidden danger of noncardiac drugs. J. Cardiovasc. Electrophysiol. (1998) 9:1114-1116.
178. MILON D, DAUBERT JC, SAINT-MARC C, GOUFFAULT J: [Torsade de pointes. Apropos of 54 cases]. Ann. Fr. Anesth. Reanim. (1982) 1 513-520. French.
179. POURMOGHADDAS A, HEKMATNIA A: The relationship between QTc interval and cardiac autonomic neuropathy in diabetes mellitus. Mol. Cell Biochem. (2003) 249:125-128.
180. VEGLIO M, CHINAGLIA A, CAVALLO PERIN P: The clinical utility of QT interval assessment in diabetes. Diabetes Nutr. Metab. (2000) 13:356-365.
181. VEGLIO M, SIVIERI R, CHINAGLIA A, SCAGLIONE L, CAVALLO-PERIN P: QT interval prolongation and mortality in Type 1 diabetic patients: A 5-year cohort prospective study. Neuropathy Study Group of the Italian Society of the Study of Diabetes, Piemonte Affiliate. Diabetes Care (2000) 23:1381-1383.
182. WHITSEL EA, BOYKO EJ, SISCOVICK DS: Reassessing the role of QTc in the diagnosis of autonomic failure among patients with diabetes a meta-analysis. Diabetes Care (2000) 23: 241-247.
183. ROSSING P, BREUM L, MAJOR-PEDERSEN A et al.: Prolonged QTc interval predicts mortality in patients with Type 1 diabetes mellitus. Diabet. Med. (2001) 18:199-205.
184. KOCHERIL AG, BOKHARI SA, BATSFORD WP, SINUSAS AJ: Long QTc and torsades de pointes in human immunodeficiency virus disease. Pacing Clin. Electrophysiol. (1997) 20:2810-2816.
185. RODRIGUEZ I, KILBORN MJ, LIU XK, PEZZULLO JC, WOOSLEY RL: Drug-induced QT prolongation in women during the menstrual cycle. JAMA (2001) 285:1322-1326.
186. BAILEY DC, SPENCE JD, MUNOZ C, ARNOLD JM: Interaction of citrus juices with felodipine and nifedipine. Lancet (1991) 337 268-269.
187. BAILEY DC, MALCOLM J, ARNOLD O, SPENCE JD: Grapefruit juice-drug interactions. Br. J. Clin. Pharmacol. (1998) 46 101-110.
188. FUHR U: Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance. Drug Saf. (1998) 18 251-272.
189. HUANG SM, HALL SD, WATKINS P et al.: Drug interactions with herbal products and grapefruit juice: a conference report. Clin. Pharmacol. Ther. (2004) 75:1-12.
190. HARRIS RZ, JANG GR, TSUNODA S: Dietary effects on drug metabolism and transport. Clin. Pharmacokinet. (2003) 42 1071-1088.
191. ZHOU S, GAO Y, JIANG W, HUANG M, XU A, PAXTON JW: Interactions of herbs with cytochrome P450. Drug Metab. Rev. (2003) 35:35-98.
192. BRAZIER NC, LEVINE MA: Drug-herb interaction among commonly used conventional medicines: a compendium for health care professionals. Am. J. Ther. (2003) 10:163-169.
193. MONTERREY-RODRIGUEZ J, FELIU JF, RIVERA-MIRANDA GC: Interaction between warfarin and mango fruit. Ann. Pharmacother. (2002) 36:940-941.
194. DESTA Z, SOUKHOVA N, MOROCHO AM, FLOCKHART DA: Stereoselective metabolism of cisapride and enantiomer-enantiomer interaction in human cytochrome P450 enzymes: major role of CYP3A: J. Pharmacol. Exp. Ther. (2001) 298:508-520.
195. DESTA Z, KIVISTO KT, LILJA JJ et al.: Effect of grapefruit juice on the stereoselective pharmacokinetics of cisapride and cardiac QTc interval in healthy volunteers. Clin. Pharmacol. Ther. (2001) 69:P82 (abstract).
196. ANON: Severe cardiac arrhythmia on cisapride. Prescrire Int. (2000) 9:144-145.
197. NAPOLITANO C, SCHWARTZ PJ, BROWN AM et al.: Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J. Cardiovasc. Electrophysiol. (2000) 11:691-696.
198. MAKITA N, HORIE M, NAKAMURA T et al.: Drug-induced long QT syndrome associated with a subclinical SCN5A mutation. Circulation (2002) 106:1269-1274.
199. SMALLEY W, SHATIN D, WYSOWSKI DK et al.: Contraindicated use of cisapride: impact of Food and Drug Administration regulatory action. JAMA (2000) 284:3036-3039.
200. KRASUCKI C, MCFARLANE F: Electrocardiograms, high-dose antipsychotic treatment and College guidelines. Psychiatric Bull. (1996) 20:326-330.
201. SHAH RR: Drug-induced hepatotoxicity: pharmacokinetic perspectives and strategies for risk reduction. Adverse Drug React. Toxicol. Rev. (1999) 18:181-233.
202. VAN LANCEN IM, BIRNIE E, LESCHOT NJ, BONSEL GJ, WILDE AA: Genetic knowledge and counselling skills of Dutch cardiologists: sufficient for the genomics era? Eur. Heart J. (2003) 24 560-566.